Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)

Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)

<p>Abstract</p> <p>Background</p> <p>Multiple farnesylated proteins are involved in signal transduction in cancer. Farnesyltransferase inhibitors (FTIs) have been developed as a strategy to inhibit the function of these proteins. As FTIs inhibit proliferation of melanom...

Full description

Bibliographic Details
Main Authors: Gajewski Thomas F, Salama April KS, Niedzwiecki Donna, Johnson Jeffrey, Linette Gerald, Bucher Cynthia, Blaskovich Michelle A, Sebti Said M, Haluska Frank
Format: Article
Language:English
Published: BMC 2012-12-01
Series:Journal of Translational Medicine
Subjects:
Melanoma
Farnesyltransferase inhibitor
Tipifarnib
R11577
RAS
T cell activation
Online Access:http://www.translational-medicine.com/content/10/1/246

Internet

http://www.translational-medicine.com/content/10/1/246

Similar Items